Lower-risk Myelodysplastic Syndromes: Data Updates and Evolving Treatment Paradigms in the Frontline Setting

Ralph Boccia, MD, FACP, and Hetty Carraway, MD, review Myelodysplastic Syndromes [MDS] risk stratification criteria used in their practices.

Hetty Carraway, MD, highlights the importance of early diagnosis across all patients with MDS.

Expert oncologists discuss standard-of-care frontline treatments for patients with lower-risk MDS.

Ralph Boccia, MD, FACP, shares his clinical experience using luspatercept to treat patient with lower-risk MDS.

Oncologists review study design and discuss key safety and efficacy data of the COMMANDS trial investigating luspatercept in frontline setting in patients with lower-risk MDS.

Expert oncologists discuss management strategies for patients with lower-risk MDS considering upcoming treatment options.

Ralph Boccia, MD, FACP, highlights emerging therapies and the importance of next-generation sequencing for patients with MDS.

Expert oncologists discuss unmet needs and share final thoughts on the future of treatment of patients with lower-risk MDS.